Published in J Am Coll Cardiol on June 25, 2010
The Prognostic Significance of Fibrosis Detection in Cardiomyopathy | NCT00930735
The incidence, pattern, and prognostic value of left ventricular myocardial scar by late gadolinium enhancement in patients with atrial fibrillation . J Am Coll Cardiol (2013) 2.76
Myofibroblast-mediated mechanisms of pathological remodelling of the heart. Nat Rev Cardiol (2012) 2.03
European Cardiovascular Magnetic Resonance (EuroCMR) registry--multi national results from 57 centers in 15 countries. J Cardiovasc Magn Reson (2013) 1.60
Mechanisms of disease: hypertrophic cardiomyopathy. Nat Rev Cardiol (2011) 1.55
Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson (2012) 1.51
T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy. Circ Cardiovasc Imaging (2013) 1.35
The role of cardiovascular magnetic resonance in pediatric congenital heart disease. J Cardiovasc Magn Reson (2011) 1.34
The diagnosis of hypertrophic cardiomyopathy by cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2012) 1.32
Myofibroblasts: trust your heart and let fate decide. J Mol Cell Cardiol (2013) 1.25
Diffuse myocardial fibrosis in hypertrophic cardiomyopathy can be identified by cardiovascular magnetic resonance, and is associated with left ventricular diastolic dysfunction. J Cardiovasc Magn Reson (2012) 1.18
Prevalence and distribution of late gadolinium enhancement in a large population of patients with Duchenne muscular dystrophy: effect of age and left ventricular systolic function. J Cardiovasc Magn Reson (2013) 1.18
Diagnostic and prognostic value of cardiovascular magnetic resonance in non-ischaemic cardiomyopathies. J Cardiovasc Magn Reson (2012) 1.17
Effect of sleep apnea and continuous positive airway pressure on cardiac structure and recurrence of atrial fibrillation. J Am Heart Assoc (2013) 1.13
Myocardial T1 mapping: techniques and potential applications. Radiographics (2014) 1.09
2014 korean guidelines for appropriate utilization of cardiovascular magnetic resonance imaging: a joint report of the korean society of cardiology and the korean society of radiology. Korean Circ J (2014) 1.02
Reproducibility of in-vivo diffusion tensor cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson (2012) 1.02
Myocardial fibrosis burden predicts left ventricular ejection fraction and is associated with age and steroid treatment duration in duchenne muscular dystrophy. J Am Heart Assoc (2015) 1.00
Predictive value of myocardial delayed enhancement in Duchenne muscular dystrophy. Pediatr Cardiol (2014) 0.99
Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines. Am J Cardiol (2012) 0.99
Hypertrophic cardiomyopathy in 2012. Circulation (2012) 0.98
In vivo MRI characterization of progressive cardiac dysfunction in the mdx mouse model of muscular dystrophy. PLoS One (2012) 0.98
Predictive Values of N-Terminal Pro-B-Type Natriuretic Peptide and Cardiac Troponin I for Myocardial Fibrosis in Hypertrophic Obstructive Cardiomyopathy. PLoS One (2016) 0.95
Right ventricular dysfunction is a predictor of non-response and clinical outcome following cardiac resynchronization therapy. J Cardiovasc Magn Reson (2011) 0.92
Coronary microvascular ischemia in hypertrophic cardiomyopathy - a pixel-wise quantitative cardiovascular magnetic resonance perfusion study. J Cardiovasc Magn Reson (2014) 0.92
Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. JACC Heart Fail (2013) 0.91
Characteristic cardiac phenotypes are detected by cardiovascular magnetic resonance in patients with different clinical phenotypes and genotypes of mitochondrial myopathy. J Cardiovasc Magn Reson (2015) 0.90
Focal energy deprivation underlies arrhythmia susceptibility in mice with calcium-sensitized myofilaments. Circ Res (2013) 0.89
Myocardial fibrosis detected by cardiac CT predicts ventricular fibrillation/ventricular tachycardia events in patients with hypertrophic cardiomyopathy. J Cardiovasc Comput Tomogr (2013) 0.89
Prognostic value of contrast-enhanced cardiac magnetic resonance imaging in patients with newly diagnosed non-ischemic cardiomyopathy: cohort study. PLoS One (2013) 0.89
Prediction of sudden cardiac death: next steps in pursuit of effective methodology. J Interv Card Electrophysiol (2011) 0.89
Primary prevention of sudden cardiac death in a low-risk child with familial hypertrophic cardiomyopathy: the role of cardiac magnetic resonance imaging. Clin Res Cardiol (2013) 0.88
The relationship between electrocardiographic changes and CMR features in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. Int J Cardiovasc Imaging (2014) 0.88
Targeting cardiac fibrosis: a new frontier in antiarrhythmic therapy? Am J Cardiovasc Dis (2011) 0.87
High signal intensity on T2-weighted cardiac magnetic resonance imaging correlates with the ventricular tachyarrhythmia in hypertrophic cardiomyopathy. Heart Vessels (2012) 0.87
Accuracy and reproducibility of semi-automated late gadolinium enhancement quantification techniques in patients with hypertrophic cardiomyopathy. J Cardiovasc Magn Reson (2014) 0.86
Relationship of delayed enhancement by magnetic resonance to myocardial perfusion by positron emission tomography in hypertrophic cardiomyopathy. Circ Cardiovasc Imaging (2013) 0.86
Prognostic significance of late gadolinium enhancement quantification in cardiac magnetic resonance imaging of hypertrophic cardiomyopathy with systolic dysfunction. Heart Vessels (2015) 0.85
Effects of myocardial fibrosis assessed by MRI on dynamic left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy: a retrospective database analysis. BMJ Open (2012) 0.85
Global longitudinal strain and left atrial volume index improve prediction of appropriate implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy patients. Int J Cardiovasc Imaging (2014) 0.84
Aetiology of sudden cardiac death in sport: a histopathologist's perspective. Br J Sports Med (2012) 0.84
Contrast-free detection of myocardial fibrosis in hypertrophic cardiomyopathy patients with diffusion-weighted cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2015) 0.84
Cardiac computed tomographic imaging to evaluate myocardial scarring/fibrosis in patients with hypertrophic cardiomyopathy: a comparison with cardiac magnetic resonance imaging. Int J Cardiovasc Imaging (2012) 0.84
Cardiomyopathies: focus on cardiovascular magnetic resonance. Br J Radiol (2011) 0.83
Oxidative stress, fibrosis, and early afterdepolarization-mediated cardiac arrhythmias. Front Physiol (2013) 0.82
Are There Deleterious Cardiac Effects of Acute and Chronic Endurance Exercise? Physiol Rev (2016) 0.82
Quantifying late gadolinium enhancement on CMR provides additional prognostic information in early risk-stratification of nonischemic cardiomyopathy: a cohort study. BMC Cardiovasc Disord (2014) 0.81
Molecular networks underlying myofibroblast fate and fibrosis. J Mol Cell Cardiol (2016) 0.81
Heart failure in patients with normal coronary anatomy: diagnostic algorithm and disease pattern of various etiologies as defined by cardiac MRI. Cardiovasc Diagn Ther (2012) 0.81
Late gadolinium enhancement as a potential marker of increased perioperative risk in aortic valve replacement. Interact Cardiovasc Thorac Surg (2012) 0.81
2014 Korean guidelines for appropriate utilization of cardiovascular magnetic resonance imaging: a joint report of the Korean Society of Cardiology and the Korean Society of Radiology. Korean J Radiol (2014) 0.81
Cardiac fibrosis as a determinant of ventricular tachyarrhythmias. J Arrhythm (2014) 0.80
Low prevalence of fibrosis in thalassemia major assessed by late gadolinium enhancement cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2011) 0.80
Effect of Late Gadolinium Enhancement on the Recovery of Left Ventricular Systolic Function After Pulmonary Vein Isolation. J Am Heart Assoc (2016) 0.80
Prognosis in hypertrophic cardiomyopathy with contrast-enhanced cardiac magnetic resonance: the future looks bright. J Am Coll Cardiol (2010) 0.80
Patterns of late gadolinium enhancement in Duchenne muscular dystrophy carriers. J Cardiovasc Magn Reson (2014) 0.80
Rest perfusion abnormalities in hypertrophic cardiomyopathy: correlation with myocardial fibrosis and risk factors for sudden cardiac death. Clin Radiol (2015) 0.80
Assessment of myocardial fibrosis and coronary arteries in hypertrophic cardiomyopathy using combined arterial and delayed enhanced CT: comparison with MR and coronary angiography. Eur Radiol (2012) 0.80
Hypertrophic cardiomyopathy and ultra-endurance running - two incompatible entities? J Cardiovasc Magn Reson (2011) 0.79
Circulating matrix metalloproteinases in adolescents with hypertrophic cardiomyopathy and ventricular arrhythmia. Circ Heart Fail (2012) 0.79
Ventricular structure, function, and focal fibrosis in anabolic steroid users: a CMR study. Eur J Appl Physiol (2014) 0.79
Fibroblast-Specific Genetic Manipulation of p38 MAPK in vivo Reveals its Central Regulatory Role in Fibrosis. Circulation (2017) 0.78
Incremental prognostic value of the SYNTAX score to late gadolinium-enhanced magnetic resonance images for patients with stable coronary artery disease. Heart Vessels (2015) 0.78
Investigation of cardiomyopathy using cardiac magnetic resonance imaging part 1: Common phenotypes. World J Cardiol (2012) 0.78
Influence of phase correction of late gadolinium enhancement images on scar signal quantification in patients with ischemic and non-ischemic cardiomyopathy. J Cardiovasc Magn Reson (2015) 0.78
Imaging for assessment of sudden death risk: current role and future prospects. Europace (2016) 0.78
Quantification and significance of diffuse myocardial fibrosis and diastolic dysfunction in childhood hypertrophic cardiomyopathy. Pediatr Cardiol (2015) 0.78
Relationship of basal-septal fibrosis with LV outflow tract obstruction in hypertrophic cardiomyopathy: insights from cardiac magnetic resonance analysis. Int J Cardiovasc Imaging (2015) 0.78
Genotype-Dependent and -Independent Calcium Signaling Dysregulation in Human Hypertrophic Cardiomyopathy. Circulation (2016) 0.78
Cardiovascular magnetic resonance: Diagnostic utility and specific considerations in the pediatric population. World J Clin Pediatr (2016) 0.78
Effect of myocyte-fibroblast coupling on the onset of pathological dynamics in a model of ventricular tissue. Sci Rep (2017) 0.77
Native T1 mapping and extracellular volume fraction measurement for assessment of right ventricular insertion point and septal fibrosis in chronic thromboembolic pulmonary hypertension. Eur Radiol (2016) 0.77
Role of cardiac MRI in the assessment of nonischemic cardiomyopathies. Methodist Debakey Cardiovasc J (2013) 0.77
Cardiac magnetic resonance imaging for the investigation of cardiovascular disorders. Part 1: current applications. Tex Heart Inst J (2014) 0.77
Impact of cardiac magnetic resonance imaging in non-ischemic cardiomyopathies. World J Cardiol (2016) 0.77
Correlation between ECG abnormalities and cardiac parameters in highly trained asymptomatic male endurance athletes: evaluation using cardiac magnetic resonance imaging. Int J Cardiovasc Imaging (2012) 0.77
In hypertrophic cardiomyopathy reduction of relative resting myocardial blood flow is related to late enhancement, T2-signal and LV wall thickness. PLoS One (2012) 0.77
Histologic validation of myocardial fibrosis measured by T1 mapping: a systematic review and meta-analysis. J Cardiovasc Magn Reson (2016) 0.76
Magnetic resonance imaging for characterizing myocardial diseases. Int J Cardiovasc Imaging (2017) 0.76
Myocardial perfusion abnormality in the area of ventricular septum-free wall junction and cardiovascular events in nonobstructive hypertrophic cardiomyopathy. Int J Cardiovasc Imaging (2011) 0.76
Cardiomyopathies: Myocardial fibrosis assessed by CMR to predict events in HCM. Nat Rev Cardiol (2010) 0.76
Association of noninvasively measured left ventricular mechanics with in vitro muscle contractile performance: a prospective study in hypertrophic cardiomyopathy patients. J Am Heart Assoc (2014) 0.76
Myocyte-fibroblast communication in cardiac fibrosis and arrhythmias: Mechanisms and model systems. J Mol Cell Cardiol (2016) 0.76
Myocardial fibrosis and quality of life in patients with non-ischemic cardiomyopathy: a cardiovascular magnetic resonance imaging study. Int J Cardiovasc Imaging (2012) 0.76
High-resolution 3-dimensional late gadolinium enhancement scar imaging in surgically corrected Tetralogy of Fallot: clinical feasibility of volumetric quantification and visualization. J Cardiovasc Magn Reson (2014) 0.76
Myocardial Native T1 Time in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol (2016) 0.76
MRI classification of asymmetric septal hypertrophic cardiomyopathy and its relation to the presence of risk factors. Int J Cardiovasc Imaging (2012) 0.76
Surgical correction of hypertrophic obstructive cardiomyopathy in a patient with severe hypertrophy and septal myocardial fibrosis. Interact Cardiovasc Thorac Surg (2012) 0.75
The Role of Cardiac MRI in the Diagnosis and Risk Stratification of Hypertrophic Cardiomyopathy. Arrhythm Electrophysiol Rev (2016) 0.75
Risk assessment in hypertrophic cardiomyopathy: contemporary guidelines hampered by insufficient evidence. Heart (2013) 0.75
ECG characteristics according to the presence of late gadolinium enhancement on cardiac MRI in hypertrophic cardiomyopathy. Open Heart (2014) 0.75
High sensitivity of late gadolinium enhancement for predicting microscopic myocardial scarring in biopsied specimens in hypertrophic cardiomyopathy. PLoS One (2014) 0.75
Ex-vivo Assessment of Coronary Artery Atherosclerosis by Magnetic Resonance Imaging: Correlation with Histopathology. Open Cardiovasc Med J (2014) 0.75
Cardiovascular Magnetic Resonance Imaging of Myocardial Interstitial Expansion in Hypertrophic Cardiomyopathy. Curr Cardiovasc Imaging Rep (2014) 0.75
An unexpected case of ventricular fibrillation cardiac arrest in a Caucasian female. BMJ Case Rep (2014) 0.75
Echocardiography as a Screening Test for Myocardial Scarring in Children with Hypertrophic Cardiomyopathy. Int J Pediatr (2016) 0.75
Insights and challenges in hypertrophic cardiomyopathy, 2012. Herzschrittmacherther Elektrophysiol (2012) 0.75
Utility of magnetic resonance imaging in the evaluation of left ventricular thickening. Insights Imaging (2017) 0.75
Aborted sudden cardiac death (SCD) in a patient with hypertrophic cardiomyopathy (HCM) with low-risk factors for SCD. BMJ Case Rep (2013) 0.75
Hypertrophic cardiomyopathy: refining the lens of cardiac magnetic resonance to evaluate late gadolinium enhancement. J Am Coll Cardiol (2012) 0.75
Clinical Significance of Late Enhancement and Regional Wall Remodeling Assessed by 3T Magnetic Resonance Imaging. Clin Med Insights Cardiol (2015) 0.75
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med (2010) 15.71
The zebrafish reference genome sequence and its relationship to the human genome. Nature (2013) 8.52
Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation (2010) 6.71
Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J (2007) 6.34
Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet (2012) 6.25
Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet (2002) 6.11
Truncations of titin causing dilated cardiomyopathy. N Engl J Med (2012) 6.07
Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol (2002) 5.74
Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation (2010) 5.68
Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol (2006) 5.58
Abnormal subendocardial perfusion in cardiac syndrome X detected by cardiovascular magnetic resonance imaging. N Engl J Med (2002) 5.42
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J (2014) 5.21
Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA (2013) 5.19
Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. JACC Cardiovasc Imaging (2011) 4.78
A new diagnostic test for arrhythmogenic right ventricular cardiomyopathy. N Engl J Med (2009) 4.54
Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol (2003) 4.36
T1 mapping for myocardial extracellular volume measurement by CMR: bolus only versus primed infusion technique. JACC Cardiovasc Imaging (2013) 4.21
Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria. Eur Heart J (2010) 4.13
Standardized image interpretation and post processing in cardiovascular magnetic resonance: Society for Cardiovascular Magnetic Resonance (SCMR) board of trustees task force on standardized post processing. J Cardiovasc Magn Reson (2013) 3.87
Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer. J Clin Oncol (2011) 3.73
Diagnosis of left-ventricular non-compaction in patients with left-ventricular systolic dysfunction: time for a reappraisal of diagnostic criteria? Eur Heart J (2007) 3.65
Remodeling of myocyte gap junctions in arrhythmogenic right ventricular cardiomyopathy due to a deletion in plakoglobin (Naxos disease). Heart Rhythm (2004) 3.54
Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging (2013) 3.53
Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J (2005) 3.50
Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J (2013) 3.50
Left-dominant arrhythmogenic cardiomyopathy: an under-recognized clinical entity. J Am Coll Cardiol (2008) 3.42
Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. N Engl J Med (2016) 3.40
Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest (2002) 3.33
Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J (2006) 3.22
Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance. Am Heart J (2004) 3.15
Comprehensive validation of cardiovascular magnetic resonance techniques for the assessment of myocardial extracellular volume. Circ Cardiovasc Imaging (2013) 3.14
A single breath-hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging (2003) 3.11
Novel mutation in desmoplakin causes arrhythmogenic left ventricular cardiomyopathy. Circulation (2005) 3.11
The role of cardiovascular magnetic resonance in patients presenting with chest pain, raised troponin, and unobstructed coronary arteries. Eur Heart J (2007) 3.11
Natural history and familial characteristics of isolated left ventricular non-compaction. Eur Heart J (2004) 3.02
Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Int J Cardiovasc Imaging (2002) 2.95
Switching statins. BMJ (2006) 2.94
Right ventricular function in adults with repaired tetralogy of Fallot assessed with cardiovascular magnetic resonance imaging: detrimental role of right ventricular outflow aneurysms or akinesia and adverse right-to-left ventricular interaction. J Am Coll Cardiol (2002) 2.87
Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2008) 2.85
Left ventricular mass: reliability of M-mode and 2-dimensional echocardiographic formulas. Hypertension (2002) 2.77
Coronary artery bypass surgery with or without mitral valve annuloplasty in moderate functional ischemic mitral regurgitation: final results of the Randomized Ischemic Mitral Evaluation (RIME) trial. Circulation (2012) 2.71
Midwall fibrosis is an independent predictor of mortality in patients with aortic stenosis. J Am Coll Cardiol (2011) 2.66
Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol (2004) 2.59
Clinical and genetic characterization of families with arrhythmogenic right ventricular dysplasia/cardiomyopathy provides novel insights into patterns of disease expression. Circulation (2007) 2.56
Climate warming, marine protected areas and the ocean-scale integrity of coral reef ecosystems. PLoS One (2008) 2.55
Coronary calcium measurement improves prediction of cardiovascular events in asymptomatic patients with type 2 diabetes: the PREDICT study. Eur Heart J (2008) 2.52
Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Respir Crit Care Med (2005) 2.49
Frequency and clinical expression of cardiac troponin I mutations in 748 consecutive families with hypertrophic cardiomyopathy. J Am Coll Cardiol (2004) 2.49
Mutations in the muscle LIM protein and alpha-actinin-2 genes in dilated cardiomyopathy and endocardial fibroelastosis. Mol Genet Metab (2003) 2.42
Hypertrophic cardiomyopathy. Lancet (2004) 2.41
Severe disease expression of cardiac troponin C and T mutations in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol (2004) 2.40
Recommendations for interpretation of 12-lead electrocardiogram in the athlete. Eur Heart J (2009) 2.37
Reference right ventricular systolic and diastolic function normalized to age, gender and body surface area from steady-state free precession cardiovascular magnetic resonance. Eur Heart J (2006) 2.35
On T2* magnetic resonance and cardiac iron. Circulation (2011) 2.33
The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol (2004) 2.31
Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. J Am Coll Cardiol (2012) 2.28
Arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in the desmosomal gene desmocollin-2. Am J Hum Genet (2006) 2.26
Impact of primary coronary angioplasty delay on myocardial salvage, infarct size, and microvascular damage in patients with ST-segment elevation myocardial infarction: insight from cardiovascular magnetic resonance. J Am Coll Cardiol (2009) 2.24
Prospective evaluation of relatives for familial arrhythmogenic right ventricular cardiomyopathy/dysplasia reveals a need to broaden diagnostic criteria. J Am Coll Cardiol (2002) 2.22
Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol (2002) 2.21
Non-atherosclerotic coronary artery disease associated with sudden cardiac death. Heart (2010) 2.21
Updates in cardiac amyloidosis: a review. J Am Heart Assoc (2012) 2.21
Can ROTEM thromboelastometry predict postoperative bleeding after cardiac surgery? J Cardiothorac Vasc Anesth (2008) 2.20